U.S. pharma giant copyright scrapped two experimental weight loss capsules past yr—a after-everyday pill, lotiglipron, because of elevated liver enzymes plus a twice-each day pill, danuglipron, on account of solid Negative effects—but CEO Albert Bourla has said the company is set to